XORTX Therapeutics Inc.
XRTX.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 420.60K | 546.60K | 834.60K | 513.80K | 516.60K |
| Depreciation & Amortization | 26.10K | 25.90K | 33.00K | 32.10K | 24.40K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 454.50K | 607.30K | 935.40K | 619.50K | 675.10K |
| Operating Income | -454.50K | -607.30K | -935.40K | -619.50K | -675.10K |
| Income Before Tax | 122.50K | -587.00K | 170.10K | -3.02M | 2.70M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 122.50K | -587.00K | 170.10K | -3.02M | 2.70M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 122.50K | -587.00K | 170.10K | -3.02M | 2.70M |
| EBIT | -454.50K | -607.30K | -935.40K | -619.50K | -675.10K |
| EBITDA | -813.50K | -597.20K | -887.90K | -605.70K | -667.10K |
| EPS Basic | 0.04 | -0.20 | 0.06 | -1.24 | 1.35 |
| Normalized Basic EPS | 0.02 | -0.13 | 0.04 | -0.78 | 0.84 |
| EPS Diluted | 0.04 | -0.20 | 0.06 | -1.24 | 1.35 |
| Normalized Diluted EPS | 0.02 | -0.13 | 0.04 | -0.78 | 0.84 |
| Average Basic Shares Outstanding | 3.28M | 2.90M | 2.90M | 2.43M | 2.00M |
| Average Diluted Shares Outstanding | 3.28M | 2.90M | 2.90M | 2.43M | 2.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
